BluePrint Orphan
  • About
    • Team
    • Development Blog
    • White Papers
    • Contact Us
  • Services
    • Market Access and Forecasting
    • Data Management and Analytics
    • Global Pricing and Reimbursement
    • HEOR
    • Marketing and Messaging Analytics
    • Stakeholder Advisory Boards
  • Products
    • Indications
    • Therapeutics
  • BUSINESS DEVELOPMENT
    • RareValue >
      • RareValue Example
    • Out-License
    • On-Site Workshop


PERSPECTIVES ON BIOPHARMA TRENDS

Asset Identification Series

11/20/2015

 

Early Stage Asset Identification


​In the first part of this two part series, we will be discussing techniques and associated challenges in identifying potential assets early in the development process. Please click here for the second part of this series – “Asset Valuation and Risk Assessment“.
 
Rationale
The cost of drug development, from initial research through NME approval, now exceeds $1.3 billion in out-of-pocket expenses [1], resulting in a substantial commitment as well as a serious financial drain on pharmaceutical companies. In order to combat these high barriers and reduce the strain on internal research and development teams, it is becoming more common to turn to outside sources [2]. Options for outsourcing can include identifying target groups for acquisition, as well as evaluating specific technologies for licensing opportunities. This article will provide a framework for the asset identification and selection process.

Read More

    Archives

    May 2020
    February 2019
    May 2018
    January 2017
    December 2016
    November 2016
    March 2016
    November 2015
    September 2015
    June 2015
    December 2014

    Topics

    All
    Business Development
    Gene Therapy
    Licensing
    Ophthalmic Therapy
    Rare Disease
    Regenerative Therapy
    Small Molecule
    Stem Cell Therapy
    Therapeutic Development

Home

Team

Products

Business Development

Contact

info@blueprintorphan.com
  • About
    • Team
    • Development Blog
    • White Papers
    • Contact Us
  • Services
    • Market Access and Forecasting
    • Data Management and Analytics
    • Global Pricing and Reimbursement
    • HEOR
    • Marketing and Messaging Analytics
    • Stakeholder Advisory Boards
  • Products
    • Indications
    • Therapeutics
  • BUSINESS DEVELOPMENT
    • RareValue >
      • RareValue Example
    • Out-License
    • On-Site Workshop